Effect of vasoactive intestinal polypeptide (VIP) upon myometrial blood flow in non-pregnant rabbit.

Ottesen B, Fahrenkrug J

Acta physiologica Scandinavica1 Jun 1981Cited by 31 (Europe PMC)

PMID7315413DOI10.1111/j.1748-1716.1981.tb06804.xPepBankPUB-07315413

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In non-pregnant rabbits, VIP increased myometrial blood flow in a dose-dependent manner.
In plain wordsIn rabbits, VIP raised blood flow in the uterine muscle, and higher doses raised it more.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseMyometrial blood flow
Study
rabbitn: not reported in source
non-pregnant rabbit, myometrial blood flow by xenon-133 washout
Outcome group
Vascular function · Reproductive and sexual health
Studied dose
5, 50, 500 pmol/min/kgAs given in this study (rabbit).
Source sentences
Summary
VIP increased MBF dose-dependently.
1 context sentence(design, population, supporting numbers)
Summary · context
For that reason we investigated the dose-relationship between VIP (5, 50, 500 pmol . min-1 . kg-1) and myometrial blood flow (MBF) using Xenon-133 washout technique.
Report a problemFND-0731541301
02AnimalAnimal study (in vivo)Activity measurement
In non-pregnant rabbits, VIP was 100 times more potent than acetylcholine on a molar basis for increasing myometrial blood flow.
In plain wordsIn rabbits, VIP was 100 times more potent than acetylcholine in raising uterine muscle blood flow.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePotency of VIP versus acetylcholine on myometrial blood flow
Study
rabbitn: not reported in source
non-pregnant rabbit, myometrial blood flow by xenon-133 washout
Comparator
Acetylcholine
Outcome group
Vascular function · Reproductive and sexual health
Studied dose
5, 50, 500 pmol/min/kgAs given in this study (rabbit).
Measurements
Relative molar potency versus acetylcholine
100 fold
myometrial blood flow
Source sentences
Summary
VIP was on molar base 100 times more potent than acetylcholine.
1 context sentence(design, population, supporting numbers)
Summary · context
For that reason we investigated the dose-relationship between VIP (5, 50, 500 pmol . min-1 . kg-1) and myometrial blood flow (MBF) using Xenon-133 washout technique.
Report a problemFND-0731541302
03AnimalAnimal study (in vivo)Mechanism
In non-pregnant rabbits, the VIP-induced increase in myometrial blood flow was not antagonized by atropine, adrenergic blocking agents or naloxone.
In plain wordsIn rabbits, atropine, adrenergic blockers and naloxone did not block the rise in uterine blood flow caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeAntagonism of the VIP blood flow increase by atropine, adrenergic blockers or naloxone
Study
rabbitn: not reported in source
non-pregnant rabbit, myometrial blood flow by xenon-133 washout
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
5, 50, 500 pmol/min/kgAs given in this study (rabbit).
Source sentences
Summary
The action of VIP seems to be direct on vascular smooth muscle rather than mediated by other neurotransmitters, because the MBF increase was not antagonized by atropine, adrenergic blocking agents or naloxone.
1 context sentence(design, population, supporting numbers)
Summary · context
For that reason we investigated the dose-relationship between VIP (5, 50, 500 pmol . min-1 . kg-1) and myometrial blood flow (MBF) using Xenon-133 washout technique.
Report a problemFND-0731541303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.